These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 30408079)

  • 41. Cost-effectiveness of sofosbuvir plus ribavirin with or without pegylated interferon for the treatment of chronic hepatitis C in Italy.
    Cure S; Guerra I; Cammà C; Craxì A; Carosi G
    J Med Econ; 2015; 18(9):678-90. PubMed ID: 25891129
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cost-Effectiveness of Genotype 1 Chronic Hepatitis C Virus Treatments in Patients Coinfected with Human Immunodeficiency Virus in the United States.
    Saab S; Virabhak S; Parisé H; Johnson S; Wang A; Misurski D; Gonzalez YS; Juday T
    Adv Ther; 2016 Aug; 33(8):1316-30. PubMed ID: 27342742
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hepatitis Outreach Network: a practical strategy for hepatitis screening with linkage to care in foreign-born communities.
    Perumalswami PV; Factor SH; Kapelusznik L; Friedman SL; Pan CQ; Chang C; Di Clemente F; Dieterich DT
    J Hepatol; 2013 May; 58(5):890-7. PubMed ID: 23333446
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Targeted outreach hepatitis B vaccination program in high-risk adults: The fundamental challenge of the last mile.
    Mangen MJ; Stibbe H; Urbanus A; Siedenburg EC; Waldhober Q; de Wit GA; van Steenbergen JE;
    Vaccine; 2017 May; 35(24):3215-3221. PubMed ID: 28483198
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Evaluation of the cost-effectiveness of entecavir versus lamivudine in hepatitis BeAg-positive chronic hepatitis B patients.
    Yuan Y; Iloeje UH; Hay J; Saab S
    J Manag Care Pharm; 2008; 14(1):21-33. PubMed ID: 18240879
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Assessing the cost-effectiveness of treating chronic hepatitis C virus in people who inject drugs in Australia.
    Visconti AJ; Doyle JS; Weir A; Shiell AM; Hellard ME
    J Gastroenterol Hepatol; 2013 Apr; 28(4):707-16. PubMed ID: 23173753
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prevalence of Chronic Hepatitis B and C Infection in Mongolian Immigrants in the Washington, District of Columbia, Metropolitan Area, 2016-2017.
    Ha E; Kim F; Blanchard J; Juon HS
    Prev Chronic Dis; 2019 Jan; 16():E08. PubMed ID: 30676936
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cost-Effectiveness of One-Time Hepatitis C Screening Strategies Among Adolescents and Young Adults in Primary Care Settings.
    Assoumou SA; Tasillo A; Leff JA; Schackman BR; Drainoni ML; Horsburgh CR; Barry MA; Regis C; Kim AY; Marshall A; Saxena S; Smith PC; Linas BP
    Clin Infect Dis; 2018 Jan; 66(3):376-384. PubMed ID: 29020317
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The cost-effectiveness of screening for chronic hepatitis B infection in the United States.
    Eckman MH; Kaiser TE; Sherman KE
    Clin Infect Dis; 2011 Jun; 52(11):1294-306. PubMed ID: 21540206
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Universal testing for hepatitis B and hepatitis C in the emergency department: a cost-effectiveness and budget impact analysis of two urban hospitals in the United Kingdom.
    Williams J; Vickerman P; Smout E; Page EE; Phyu K; Aldersley M; Nebbia G; Douthwaite S; Hunter L; Ruf M; Miners A
    Cost Eff Resour Alloc; 2022 Nov; 20(1):60. PubMed ID: 36376920
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cost-Effectiveness of Peg-Interferon, Interferon and Oral Nucleoside Analogues in the Treatment of Chronic Hepatitis B and D Infections in China.
    Goyal A; Murray JM
    Clin Drug Investig; 2016 Aug; 36(8):637-48. PubMed ID: 27166628
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cost-effectiveness and budget impact analysis of facility-based screening and treatment of hepatitis C in Punjab state of India.
    Chugh Y; Premkumar M; Grover GS; Dhiman RK; Teerawattananon Y; Prinja S
    BMJ Open; 2021 Feb; 11(2):e042280. PubMed ID: 33589457
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cost-Effectiveness Analysis of Early Treatment of Chronic HCV with Sofosbuvir/Velpatasvir in Italy.
    Ruggeri M; Romano F; Basile M; Coretti S; Rolli FR; Drago C; Cicchetti A
    Appl Health Econ Health Policy; 2018 Oct; 16(5):711-722. PubMed ID: 30039348
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cost-effectiveness of rapid hepatitis C virus (HCV) testing and simultaneous rapid HCV and HIV testing in substance abuse treatment programs.
    Schackman BR; Leff JA; Barter DM; DiLorenzo MA; Feaster DJ; Metsch LR; Freedberg KA; Linas BP
    Addiction; 2015 Jan; 110(1):129-43. PubMed ID: 25291977
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A Microsimulation Study of the Cost-Effectiveness of Hepatitis C Virus Screening Frequencies in Hemodialysis Centers.
    Epstein RL; Pramanick T; Baptiste D; Buzzee B; Reese PP; Linas BP; Sawinski D
    J Am Soc Nephrol; 2023 Feb; 34(2):205-219. PubMed ID: 36735375
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical effectiveness and cost effectiveness of tailoring chronic hepatitis C treatment with peginterferon alpha-2b plus ribavirin to HCV genotype and early viral response: a decision analysis based on German guidelines.
    Siebert U; Sroczynski G; Aidelsburger P; Rossol S; Wasem J; Manns MP; McHutchison JG; Wong JB
    Pharmacoeconomics; 2009; 27(4):341-54. PubMed ID: 19485429
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Chronic hepatitis B and C infection in the United States: a review of current guidelines, disease burden and cost effectiveness of screening.
    Sarpel D; Baichoo E; Dieterich DT
    Expert Rev Anti Infect Ther; 2016; 14(5):511-21. PubMed ID: 27043049
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Population health impact and cost-effectiveness of monitoring inactive chronic hepatitis B and treating eligible patients in Shanghai, China.
    Toy M; Salomon JA; Jiang H; Gui H; Wang H; Wang J; Richardus JH; Xie Q
    Hepatology; 2014 Jul; 60(1):46-55. PubMed ID: 24990105
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evaluating the cost-effectiveness of existing needle and syringe programmes in preventing hepatitis C transmission in people who inject drugs.
    Sweeney S; Ward Z; Platt L; Guinness L; Hickman M; Hope V; Maher L; Iversen J; Hutchinson SJ; Smith J; Ayres R; Hainey I; Vickerman P
    Addiction; 2019 Mar; 114(3):560-570. PubMed ID: 30674091
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening.
    Hahné SJ; Veldhuijzen IK; Wiessing L; Lim TA; Salminen M; Laar Mv
    BMC Infect Dis; 2013 Apr; 13():181. PubMed ID: 23597411
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.